Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$0.18 - $0.3 $6,821 - $11,369
37,899 New
37,899 $7,000
Q4 2021

Feb 14, 2022

SELL
$2.6 - $4.18 $193,835 - $311,627
-74,552 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$3.27 - $4.76 $6,867 - $9,996
-2,100 Reduced 2.74%
74,552 $269,000
Q2 2021

Aug 12, 2021

BUY
$4.63 - $7.34 $354,898 - $562,625
76,652 New
76,652 $367,000

About NeuBase Therapeutics, Inc.


  • Ticker NBSE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,258,700
  • Description
  • NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as ...
More about NBSE
Track This Portfolio

Track Ergoteles LLC Portfolio

Follow Ergoteles LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ergoteles LLC with notifications on news.